Seoul National University · 医学
Professor Belinda Lee's research lab focuses on translational cancer research, with a strong emphasis on understanding the biological and mechanical properties of cancer microenvironments, particularly in aggressive malignancies like pancreatic and melanoma. The lab investigates molecular pathways driving tumorigenesis—such as the RB and RAS/RAF/MEK/ERK signaling axes—and explores the role of tumor stroma and extracellular matrix rheology in disease progression. It also contributes to the development of comprehensive, multi-site cancer registries to support precision oncology through robust data collection and analysis.
Figures are computed from collected data and may differ slightly.
The rheological properties of the vitreous body of the eye are believed to be a function of composition and to differ among species, as well as to vary regionally within the vitreous. These properties are essential to the mechanical functioning of the eye. Although there are gross, qualitative data on vitreous rheology available in the literature, quantitative rheological measurements on human vitreous and on eyes of other species are sparse and incomplete. The aim of the research reported in th
Axillary ultrasound has a low negative predictive value and negative ultrasound results do not exclude axillary node metastases with sufficient sensitivity to justify its routine clinical use. Clinical pathways need to consider an evidence-based approach, focusing on the criteria by which we select breast cancer patients for ALND.
http://links.lww.com/COON/A12.
Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the establishment of a series of comprehensive cancer registries across the spectrum of common solid cancers. The experience and learnings of each registry team as they develop, implement and then use collected data for a range of purposes, that informs
It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide management decisions, whether for systemic chemotherapy, molecularly targeted therapies, or immunotherapies. To date, the results for targeted agents and immunotherapies in unselected populations of ch
Research into the cyclin-dependent kinases and their inhibitors is finally coming into the forefront of clinical research in cancer. Targeted therapies such as BRAF inhibitors have led the way in improving treatment outcomes in advanced melanoma. Based on detailed genomic knowledge of melanoma it is now time to extend targeted therapies beyond BRAF to fulfill the vision of precision medicine. The p16INK4A-cyclin D-CDK4/6-retinoblastoma protein pathway (RB pathway) is dysregulated in more than 90
107 Background: Recurrence rates following upfront resection of pancreatic adenocarcinoma are high, with some benefit from adjuvant chemotherapy (AC). A biomarker that improves risk stratification and/or provides real time indication of AC benefit could improve routine clinical management and accelerate trial progress. Previous studies in pancreas cancer suggest that patients with detectable ctDNA post surgery are at an elevated risk of recurrence. Detectable ctDNA at the completion of AC may al
4101 Background: Pancreatic cancer remains a devastating disease, with the diagnosis typically being made late. ctDNA has shown promise as a screening test for various tumor types. The detection of ctDNA post curative intent surgery has been associated with a high risk of recurrence in multiple solid tumors. We explored the potential of ctDNA to improve pancreatic cancer outcomes. Methods: Data from separate US and Australian series were combined. Plasma samples were collected prior to surgery i
Open papers in the app to read, cite, and organize with AI.
